Anti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine)

N/A

Report date: 2022/03/10 17:51:08

Base Information

Drug NameAnti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine)
Drug Alias NameTAA5 CAR TFLT3 autologous chimeric antigen receptor T cellsFLT3 CAR-T cellsTAA05 cell injectionTAA5-CAR-T +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPersongen Biotherapeutics (Suzhou) Co LtdThe First Affiliated Hospital Of Soochow University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A